Completed
DNA MGPT reporting range is not required for RNA genetic testing
Class Central Classrooms beta
YouTube videos curated by Class Central.
Classroom Contents
Validation of RNA Genetic Testing for Use in a Clinical Diagnostic Setting - Ambry Genetics
Automatically move to the next video in the Classroom when playback concludes
- 1 Intro
- 2 Disclosures/ Conflict of Interest
- 3 Lecture Outline
- 4 Advancements in genetic testing
- 5 DNA-based genetic testing may miss patients with hereditary cancer or provide inconclusive results
- 6 Morphological and functional diversity of RNA
- 7 mRNA processing
- 8 RNA alternative splicing (AS)
- 9 RNA AS provides functional evidence to support variant reclassification and identification
- 10 Background of RNA genetic testing
- 11 Considerations for whole transcriptome sequencing
- 12 RNA genetic testing and DNA MGPT are performed in parallel
- 13 DNA MGPT reporting range is not required for RNA genetic testing
- 14 Aberrant splicing is determined based on data quality and comparison to healthy controls
- 15 Clinical utility and scalability of RNA genetic testing
- 16 Demographics of healthy controls
- 17 Selection of 18 tumor suppressor genes
- 18 Demographics do not confound splicing profile for 18 TSGS
- 19 Number of alternative splicing events vary by gene
- 20 Validation of RNA genetic testing with known splicing variants
- 21 Orthogonal confirmation with Clone-Seq
- 22 Pilot Data
- 23 Variants identified only with RNA genetic testing
- 24 Case #2: Exon 17 skipping in BRCAL
- 25 Case study #3: Exon 56 skipping in ATM
